Lung: what about low doses?
Khalil et al. Acta Oncol 2015: IMRT, LANSCLC, 87 cases
phase I (n=12)
only V20 < 40%
phase II (n=25)
V20 < 40%
and MLD ≤ 20 Gy.
phase III (n=50)
and MLD ≤ 20 Gy
and V5 ≤ 60%
24
without V5
with V5